PhRMA CEO Steve Ubl says the group is still fighting hard against the drug pricing provisions, but is making contingency plans — and promises — should reconciliation become law.
“Those members who vote for this bill will not get a free pass. We’ll do whatever we can to hold them accountable,” said Steve Ubl, head of the Pharmaceutical Research and Manufacturers of America. | Matt Rourke/AP
Steve Ubl, who leads the nation’s top industry group for drugmakers, is offering a final salvo to Congress as Democratic lawmakers inch closer to passing their sweeping reconciliation package that includes drug pricing measures — and threatening swift retaliation if they don’t listen, he told POLITICO. —
Ubl’s group, the Pharmaceutical Research and Manufacturers of America, or PhRMA, and its 31 board members sent a letter to every member of Congress on Thursday afternoon, urging them to vote against the package.
PhRMA, not accustomed to losing legislative fights, has waged a multimillion-dollar advocacy campaign against the drug pricing measures, and is crafting contingency plans if they fail. In addition to hinting at running campaign ads against Democrats in tough races this fall, the industry is assessing its legal options and pondering future regulatory or legislative fixes.